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INTRODUCTION  
Oxcarbazepine is an anticholinergic, 
anticonvulsant and mood stabilizing drug, used primarily  
in the treatment of epilepsy. It is also used to treat anxiety, 
bipolar mood disorders,
1
 and benign motor tics. It is 
a prodrug which is activated to eslicarbazepine in the liver. 
 
It is a structural derivative of carbamazepine, with a ketone 
in place of the carbon-carbon double bond on the 
dibenzazep ine ring. This difference helps reduce the 
impact on the liver of metabolizing the drug, and also 
prevents the serious forms 
of anemia or agranulocytosis occasionally associated 
with carbamazepine. It is thought to have the same 
mechanis m of action as carbamazepine - sodium 
channel inhibition and is generally used to treat the same 
conditions. It has been approved for monotherapy or 
adjunct therapy for partial seizures in adults and as 
adjunctive therapy for partial seizures in children age 4 to 
16 years.
2
 Its efficacy is similar to carbamazepine but 
allergic reactions and enzyme induction is low with 
oxcarbazepine.
3
 These properties support the adjunctive 
use of oxcarbazepine in the treatment of resistant patients. 
The incidence of adverse effects reported with 
oxcarbazepine ranged from 46-68%.
3,
 
4 
The most common
    
adverse effects are drowsiness, fatigue and dizziness. 
Other effects with lower incidence include headache, 
diplopia, ataxia, nystagmus, nausea, vomiting, epigastric 
discomfort and diarrhea. Elderly patients and those on high 
daily doses of oxcarbazepine (25-30 mg/day) may suffer 
from hyponatremia (in 23% cases).
5
 It causes an increase 
in the plasma concentrations of phenytoin and valproic 
acid by 20-30%. 
6, 7
 
Carbamazepine is the most common cause of Stevens -
Johnson syndrome (SJS). Recently, oxcarbazepine has also 
been shown to induce SJS, although extremely rarely. It is 
generally considered safe in comparison to carbamazepine.  
In this study, we report a rare case of oxcarbazepine-
induced toxic epidermal necrolysis of a 66 years old lady 
who was suffering from uncontrolled epilepsy due to 
chronic rheumatic heart disease (RHD) with 
cardiovascular accident (CVA). 
METHODS AND RES ULTS (CAS E REPORT) 
 A 66 years old lady who had past history of rheumatic 
heart disease with cardiovascular accident was admitted in 
dermatology department of a tertiary care hospital for the 
treatment of rashes and itching. For the last one year 
patient was on tablet sodium valproate 200 mg three times 
daily and tab digoxin (Lanoxin 0.25 mg) once daily for 
above mentioned problem. 
One week before patient had an episode of convulsion and 
oxcarbazepine (tablet oxetol 150 mg) twice daily was 
added by a physician. Two to three days after intake of this 
drug some rashes appeared on her upper limbs. Patient 
consulted a local physician for this problem and she was 
referred to higher center for fu rther investigation and 
management. 
In higher center offensive drug was stopped and 
conservative management started.  Rashes appeared on her 
face, trunk and extremities. The patient was observed for 
progression of rashes and new erosions. It was itchy in 
nature. Due to rapid progression of the oral erosions and 
full-thickness necrotic lesions on the palms, the patient 
was provisionally diagnosed as a case of evolving Stevens 
- Johnson syndrome (SJS) or toxic epidermal necrolysis 
(TEN) and managed accordingly.  
Subsequently in one to two days rashes increased in 
severity. Ulceration appeared in oral region. It also 
appeared on face, eyelid and at upper and lower lip. She 
had problem in intake of food because her mouth was 
blistered and eroded. There was swelling over the eyelid. 
Some rashes changed to vesicle. Lesions spread all over 
the body. Vesiculation spread to legs with exfoliation. 
Ulceration at neck region was very dense. 63% of the body 
surface area was engaged. Complete hemogram, blood 
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sugar, routine examination of urine, culture sensitivity of 
the skin tissue and histopathology of the skin was done. 
Laboratory investigations showed leucocytosis and 
elevated C-reactive protein. Patient’s skin biopsy revealed 
full-thickness necrosis of the epidermis, confirming the 
diagnosis of TEN. 
She was treated main ly with corticosteroids, antihistamines 
and antimicrobials. Patient improved in a week. She was 
later discharged with necessary advice. Time taken in  
complete resolution of the lesion was 38 days. 
 DISCUSS ION 
Toxic epidermal necrolysis is a rare, life-
threatening dermatological condition that is usually 
induced by a reaction to medications.
 8
 The clinical 
features with which the patient presented were similar to 
those seen in a typical case of toxic epidermal necro lysis.
9
 
Conditions like staphylococcal scalded skin syndrome, 
herpes simplex, blistering skin diseases, mucocutaneous 
diseases and vasculitis were excluded clinically.   Further 
rechallenge with oral oxcarbazep ine was not done in the 
interest of the patient and due to ethical reasons. The 
appearance of toxic epidermal necrolysis in this patient 
who had taken oral oxcarbazep ine could not be explained 
by any other concurrent diseases or drug or chemical 
intake.  A dechallenge with oxcarbazep ine improved the 
condition. This reaction is dose unrelated and can be 
labeled as type B class of adverse effect.
10
 It can also be 
considered as probably/ likely as per causality 
assessment.
11
  
 
Figure 1: Pat ient photograph one week after intake of 
tablet oxcarbazepine  
CONCLUS ION: 
We therefore concluded that this was a case of 
oxcarbazepine-induced toxic epidermal necrolysis. With 
this case report we aim to create awareness about rare but 
potentially  fatal drug reaction like toxic epidermal 
necrolysis that can occur with oxcarbazepine and so the 
use of this drug should be carefully monitored.  
 
REFERENCES 
1. Ghaemi SN, Berv DA, Klugman J, Rosenquist KJ, Hsu DJ, 
Oxcarbazepine treatment of bipolar disorder,J Clin 
Psychiatry,2003;64(8),943-945. 
2. McNamara JO. Pharmacotherapy of epilepsies. In: Brunton 
LL, editor. Goodman & Gilman’s The Pharmacological 
Basis of Therapeutics, 11th ed. New Delhi: McGraw-HIll; 
2006. P. 513. 
3. Dam M, Ekberg R, Loyning Y, et al, A double blind study 
comparing oxcarbazepine and carbamazepine in patients 
with newly diagnosed, previously untreated epilepsy, 
Epilepsy Res 1989,3(1),70-77. 
4. Reinikainen KJ, Keranen T, Halonen T, et al, Comparison of 
oxcarbazepine and carbamazepine: a double blind study, 
Epilepsy Res 1987,1(5),284-289. 
5. Friis ML, Kristensen, Boas J, et al, Therapeutic experiences  
with 947 epileptic out patietns on oxcarbazepine treatment, 
Acta Neurologica Scandinavica 1993,87(3),224-227. 
6. Klosterskov Jensen P, Sanno V, Haring P, et al, Possible 
interaction between oxcarbazepine and an oral 
contraceptive, Epilepsia 1992,33(6),1149-1152. 
7. Battino D, Croci D, Granata T, et al, Changes unbound and 
total valproic acid concentrations after replacement of 
carbamazepine with oxcarbazepine, Therapeutic Drug 
1992,14(5),376-379. 
8. Garra, GP, "Toxic Epidermal Necrolysis", Emedicine.com, 
Retrieved on December, 2007, 13, 2007. 
9. Shinkai K, Sern RS, Wintroub BU. Cutaneous drug 
reactions. In: Longo DL, editor. Harrisons’s Principles of 
Internal Medicine, 18th ed. New Delhi: McGRAW-HILL; 
2012. p. 439. 
10. Edwards IR, Aronson JK, Adverse drug reactions: 
definitions, diagnosis and management, Lancet 
2000,356,1255-1259. 
11. Calis KA, Young LR. Clinical analysis of Adverse drug 
reactions. In: Atkinson AJ Jr, Daniels CE, Dedrick RL, 
editor. Principles of clinical pharmacology. Academic Press; 
2001. P. 326. 
